Research and therapeutic applications of silk proteins in cancer
Source abstract
Abstract
Despite the availability of advanced treatments, cancer remains the second leading cause of death worldwide. This is due to the many challenges prevailing in the research field and cancer therapy. Resistance to therapy and side effects provide major hindrances to recovery from cancer. As a result, in addition to the aim of killing cancer cells, the focus should also be on reducing or preventing side effects of the treatment. To enhance the effectiveness of cancer treatment, many researchers are studying drug delivery systems based on silk proteins: fibroin and sericin. These proteins have high biocompatibility, biodegradability, and ease of modification. Consequently, many researchers have developed several formulations of silk proteins such as scaffolds, nanoparticles, and hydrogels by combining them with other materials or drugs. This review summarizes the use of silk proteins in various forms in cancer research and therapy. The use of silk proteins to study cancer cells, to deliver cancer drugs to a target site, in cancer thermal therapy, and as an anti-cancer agent is described here.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Silk-based biomaterials and applications · RNA Interference and Gene Delivery · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Research Development and Sustenance, Malla Reddy Institute of Medical Sciences, Hyderabad, India
Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India
Center for Research Development and Sustenance, Malla Reddy Institute of Dental Sciences, Hyderabad, India
Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
References (71)
Show source-provided references
1. 10.1002/ijc.3358810.1002/ijc.33588 ↗
2. 2015
3. 2017
4. 10.1016/j.lfs.2020.11829110.1016/j.lfs.2020.118291 ↗
5. 10.5114/aoms.2016.6374310.5114/aoms.2016.63743 ↗
6. 10.1016/j.msec.2020.11165410.1016/j.msec.2020.111654 ↗
7. 10.3390/polym1501002310.3390/polym15010023 ↗
8. 10.1080/21691401.2021.187162010.1080/21691401.2021.1871620 ↗
9. 10.1016/j.colsurfb.2021.11159410.1016/j.colsurfb.2021.111594 ↗
10. 10.1038/s41401-018-0048-010.1038/s41401-018-0048-0 ↗
11. 10.1016/j.fct.2018.10.06310.1016/j.fct.2018.10.063 ↗
12. 10.3389/fbioe.2022.80083010.3389/fbioe.2022.800830 ↗
13. 10.1016/j.msec.2021.11214110.1016/j.msec.2021.112141 ↗
14. 10.1021/acsami.6b0095910.1021/acsami.6b00959 ↗
15. 10.1007/s00253-015-6948-810.1007/s00253-015-6948-8 ↗
16. 10.1186/1475-2859-3-1410.1186/1475-2859-3-14 ↗
17. 10.3390/ijms1803023710.3390/ijms18030237 ↗
18. 10.2217/nnm-2019-005810.2217/nnm-2019-0058 ↗
19. 10.3390/cancers1321538910.3390/cancers13215389 ↗
20. 10.1155/2016/817570110.1155/2016/8175701 ↗
21. Rajput SK · IOSR-JPTE · 2015 · 2 · 29
22. 10.3892/mmr.2020.1177910.3892/mmr.2020.11779 ↗
23. 10.1016/j.carbpol.2019.02.06910.1016/j.carbpol.2019.02.069 ↗
24. 10.1016/j.actbio.2018.08.03110.1016/j.actbio.2018.08.031 ↗
25. 10.4067/S0716-9760201200010000610.4067/S0716-97602012000100006 ↗
26. 10.1016/j.ijbiomac.2018.03.05810.1016/j.ijbiomac.2018.03.058 ↗
27. 10.1163/156856209X42685310.1163/156856209X426853 ↗
28. 10.1016/j.jbiosc.2008.12.01210.1016/j.jbiosc.2008.12.012 ↗
29. Aramwit P · Nat Prod Commun · 2013 · 8 · 501
30. 10.1016/j.ijpharm.2017.12.01510.1016/j.ijpharm.2017.12.015 ↗
31. 10.3390/polym1422493110.3390/polym14224931 ↗
32. 10.3390/nano1004071810.3390/nano10040718 ↗
33. 10.1186/s12951-020-00734-y10.1186/s12951-020-00734-y ↗
34. 10.21873/invivo.1281510.21873/invivo.12815 ↗
35. 10.3390/biom904012310.3390/biom9040123 ↗
36. 10.1002/bip.2323110.1002/bip.23231 ↗
37. 10.1002/mabi.20200042510.1002/mabi.202000425 ↗
38. 10.18632/oncotarget.2357410.18632/oncotarget.23574 ↗
39. 10.1152/physiol.00036.201610.1152/physiol.00036.2016 ↗
40. 10.1080/10463356.2010.1188348010.1080/10463356.2010.11883480 ↗
41. 10.12659/MSM.92293510.12659/MSM.922935 ↗
42. 10.3390/polym1309141610.3390/polym13091416 ↗
43. 10.1615/CritRevEukaryotGeneExpr.201802133110.1615/CritRevEukaryotGeneExpr.2018021331 ↗
44. 10.1039/b905802h10.1039/b905802h ↗
45. 10.1002/macp.20120040710.1002/macp.201200407 ↗
46. 10.1016/j.jconrel.2009.05.02210.1016/j.jconrel.2009.05.022 ↗
47. 10.1021/bm401759410.1021/bm4017594 ↗
48. 10.1002/mabi.20150001310.1002/mabi.201500013 ↗
49. 10.1002/mabi.20130032110.1002/mabi.201300321 ↗
50. 10.1021/bm901403910.1021/bm9014039 ↗
51. 10.1186/s12951-020-00609-210.1186/s12951-020-00609-2 ↗
52. 10.3390/polym1313204710.3390/polym13132047 ↗
53. 10.3390/polym1318316910.3390/polym13183169 ↗
54. 10.3390/molecules2616493610.3390/molecules26164936 ↗
55. 10.1016/j.msec.2021.11201910.1016/j.msec.2021.112019 ↗
56. 10.18632/oncotarget.1672310.18632/oncotarget.16723 ↗
57. 10.2147/IJN.S10863310.2147/IJN.S108633 ↗
58. 10.1021/acsbiomaterials.0c0151110.1021/acsbiomaterials.0c01511 ↗
59. 10.2147/IJN.S16610410.2147/IJN.S166104 ↗
60. 10.1080/17435390.2021.194303210.1080/17435390.2021.1943032 ↗
61. 10.7150/thno.3076510.7150/thno.30765 ↗
62. 10.3390/gels701002310.3390/gels7010023 ↗
63. 10.1080/10717544.2021.195810610.1080/10717544.2021.1958106 ↗
64. 10.1016/j.jconrel.2015.05.06210.1016/j.jconrel.2015.05.062 ↗
65. 10.3390/molecules2714456310.3390/molecules27144563 ↗
66. 10.1016/j.biomaterials.2013.07.01210.1016/j.biomaterials.2013.07.012 ↗
67. 10.7150/thno.3625210.7150/thno.36252 ↗
68. 10.1016/j.ijpharm.2018.11.03010.1016/j.ijpharm.2018.11.030 ↗
69. 10.1038/srep3103710.1038/srep31037 ↗
70. 10.1371/journal.pone.019444110.1371/journal.pone.0194441 ↗
71. 10.3390/ma1321494610.3390/ma13214946 ↗